What are the differences between statin and the shortage of cellular cholesterol content in the pathology of rhabdomyolysis ?

点击翻译按钮获取中文摘要

Statin is an inhibitor for HMGCR, which is a rate-limiting enzyme for cholesterol synthesis. Although statin is an effective drug for hypercholesterolemia, statin develops rhabdomyolysis as a side effect. To understand the mechanism of the pathogenesis of rhabdomyolysis by statin, we generated the skeletal muscle-specific HMGCR knockout mice. These mice showed the same phenotypes as rhabdomyolysis. We found that the removal of the insufficient mitochondria by autophagy was dysregulated in skeletal muscle of these mice. Next, we will determine the mechanism that mitochondria function and autophagy are dysfunctioned in skeletal muscle of HMGCR knockout mice.